...
首页> 外文期刊>Leukemia and lymphoma >MiR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia
【24h】

MiR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia

机译:MiR-29c的下调与中国慢性淋巴细胞性白血病患者的疾病侵袭性和生存不良相关

获取原文
获取原文并翻译 | 示例
           

摘要

Aberrant expression of microRNAs in chronic lymphocytic leukemia (CLL) has been reported to be associated with clinical outcome and improve prognostic stratification. The aim of this study was to explore the association of miR-29c expression with clinical parameters and survival in 53 Chinese patients with CLL. We showed that the miR-29c expression level decreased significantly from early to advanced clinical stages, and was significantly lower in patients with β2-microglobulin higher than 3.5 mg/L or with disease progression or death. With the cut-off determined by receiver operating characteristic (ROC) curve analysis, optimizing concordance with immunoglobulin heavy chain (IgVH) mutation status, miR-29c negative and positive groups were defined as including 17 and 36 patients, respectively. The miR-29c negative group had a higher percentage of patients with trisomy 12 or deletion of 11q or 17p (70.6% vs. 34.3%; p = 0.014) compared to the miR-29c positive group. The median progression-free survival and overall survival of the miR-29c negative group were 21 and 92 months, respectively, significantly shorter than in the miR-29c positive group (both not reached; p = 0.002 and p = 0.042, respectively), and miR-29c down-regulation was an independent prognostic factor for PFS. In conclusion, down-regulation of miR-29c is associated with higher tumor burden and significantly predicts short survival in Chinese patients with CLL.
机译:据报道,慢性淋巴细胞性白血病(CLL)中微小RNA的异常表达与临床结果相关,并改善了预后分层。这项研究的目的是探讨53名中国CLL患者中miR-29c表达与临床参数和生存率的关系。我们显示,从早期到晚期临床阶段,miR-29c表达水平显着降低,而β2-微球蛋白高于3.5 mg / L或患有疾病进展或死亡的患者,miR-29c表达水平显着降低。根据接受者工作特征(ROC)曲线分析确定的临界值,优化与免疫球蛋白重链(IgVH)突变状态的一致性,将miR-29c阴性和阳性组分别定义为包括17名和36名患者。与miR-29c阳性组相比,miR-29c阴性组患有三体性12或11q或17p缺失的患者比例更高(70.6%对34.3%; p = 0.014)。 miR-29c阴性组的中位无进展生存期和总生存期分别为21和92个月,明显低于miR-29c阳性组(均未达到; p = 0.002和p​​ = 0.042), miR-29c下调是PFS的独立预后因素。总之,miR-29c的下调与更高的肿瘤负担相关,并显着预测中国CLL患者的生存期短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号